Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity

Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
HIV Clinical Trials (Impact Factor: 2.14). 07/2005; 6(4):197-202. DOI: 10.1310/ED57-EU48-RK6A-E5U0
Source: PubMed

ABSTRACT Stavudine (d4T) is a nucleoside analogue approved for the treatment of HIV infection. Concern has risen due to its association with mitochondrial toxicity. Given that the toxicity might be dose-dependent, we explored prospectively whether lowering d4T doses might improve the safety profile of the drug without compromising its antiviral activity.
All HIV-infected patients seen at our institution during the first semester of year 2003 who were receiving a d4T-containing regimen and had plasma HIV RNA below 50 copies/mL for the previous 3 months were invited to participate in a trial in which half of patients reduced the dose of d4T from 40 to 30 mg bid (cases) and the other half continued with the same d4T dose (controls).
A total of 92 patients were recruited in the study: 47 cases and 45 controls. A total of 9 patients experienced virological failure during the following 12 months: 4 cases and 5 controls. No significant differences between groups were recognized for mean transaminase levels, cholesterol, triglycerides, and lactate at baseline nor over the 12-month follow-up period. Lipodystrophy was recognized in 20% of patients at baseline, without significant differences between groups, and no significant improvements were recognized in the d4T 30 mg bid arm after 12 months follow-up. However, a median significant increase of 2.23-fold in the mitochondrial DNA content in peripheral blood mononuclear cells (PBMCs) was recognized in a subset of 11 patients who reduced the d4T dose, whereas it remained unchanged in 10 controls.
A reduction in the d4T dose from 40 to 30 mg bid may ameliorate mtDNA depletion in PBMCs without compromising the antiviral activity of the drug. However, significant improvements on surrogate laboratory markers of mitochondrial toxicity or in lipoatrophy could not be recognized over 12 months follow-up.

  • Source
    • "Pilot and retrospective studies suggested that reduction in d4T dosage from 40 to 30 mg twice daily (bid), in individuals weighing less than 60 kg and possibly heavier individuals as well, may decrease the incidence of side effects, without compromising antiviral efficacy (Ait-Mohand et al., 2008; Hoffmann et al., 2009; Karara et al., 2010; Pedrol et al., 2007; Sanchez-Conde et al., 2005). However, d4T dose reduction to control toxicity remains controversial. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stavudine (d4T) is used extensively as part of HAART in resource poor settings, despite its toxicities. The revised WHO guidelines specify replacement of d4T with less toxic but more expensive drugs when feasible, and that d4T doses be standardized to 30 mg twice daily (bid) (irrespective of body-weight), from the approved 40 mg bid in adults (body-weight ≥60 kg). Therefore, an in silico population pharmacokinetic and biochemical model was utilized to compare relative efficacies of the two doses in humans. Assessment of predicted quartile ranges of simulated concentrations of the triphosphate of d4T suggested sufficient trough concentrations to inhibit wild type HIV-1 reverse transcriptase at the reduced dose, lending support to the revised WHO recommendations.
    Antiviral research 08/2011; 92(2):372-7. DOI:10.1016/j.antiviral.2011.08.004 · 3.94 Impact Factor
  • Article: Ayurveda
    [Show abstract] [Hide abstract]
    ABSTRACT: Ayurveda ist eine der ältesten und am weitesten verbreiteten ethnomedizinischen Ansätze. Ayurveda ist Sanskrit und bedeutet Lebensweisheit oder auch Lebenswissenschaft. Man versteht darunter eine traditionelle indische Heilkunde, die schätzungsweise seit etwa 3000 bis 5000Jahren praktiziert wird. Ziel einer ayurvedischen Therapie ist der Erhalt und die Wiederherstellung eines harmonischen Gleichgewichts, das durch die drei „Doshas“ (Lebensenergien), „Vata“ (Wind, Luft, Pneuma), „Pitta“ (Feuer und Wasser, Chole) und „Kapha“ (Erde und Wasser, Phlegma) gesteuert wird. Ayurvedische Behandlungsansätze haben in nichtonkologischen Studien den Nachweis einer Wirksamkeit erbracht. Im Bereich der Onkologie konnten Therapeutika identifiziert werden, die in In-vitro- und tierexperimentellen Studien Wirksamkeit zeigten. Klinische Studien mit ausreichender Aussagekraft liegen jedoch bisher nicht vor. Vor einer Selbstmedikation mit ayurvedischen Präparaten ist zu abzuraten, da viele Präparate mit Schwermetallen belastet sind. Eine ayurvedische Ernährung und Yogaübungen können auch bei Tumorpatienten bei fehlenden Kontraindikationen eingesetzt werden. Ayurveda is one of the oldest and most widely distributed ethnomedical concepts. Ayurveda is Sanskrit and means worldly wisdom or science of life. It is a traditional Indian healing culture which is thought to have been practiced for as long as 3,000-5,000 years. The aim of Ayurvedic therapy is to maintain and restore a harmonious equilibrium which is controlled by the three“doshas” (energies of life),“vata” (wind, air, ether),“pitta” (fire and water, choler) and“kapha” (earth and water, phlegm). Ayurvedic treatment applications have brought evidence of effectiveness in non-oncological studies. In the area of oncology therapeutic agents could be identified which showed effectiveness in in vitro and animal experimental studies. Clinical studies with sufficient validity have not yet been carried out. It is not advisable to attempt self-medication with Ayurvedic preparations as many are contaminated with heavy metals. Ayurvedic nutrition and Yoga exercises can be implemented in tumor patients when no contra-indications are present.
    Der Onkologe 15(8):792-798. DOI:10.1007/s00761-009-1655-7 · 0.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A panel of leading Italian specialists in infectious diseases, virologists and immunologists met in Rome in 2005 to review critical data and discuss recommendations for each of the key questions in antiretroviral therapy today: When to start treatment? How to start? When to switch? What to switch to? Whether to stop or not to stop treatment, and how? The method of a nominal group meeting was used and recommendations were graded for their strength and quality using a system based on the one adopted by the Infectious Diseases Society of America. Main conclusions are summarized and critically discussed in this consensus statement, as well as some of the most recent data supporting these recommendations are provided.
    Journal of Antimicrobial Chemotherapy 07/2006; 57(6):1055-64. DOI:10.1093/jac/dkl113 · 5.44 Impact Factor
Show more


Available from